Owlet (NYSE:OWLT – Get Free Report) and Sight Sciences (NASDAQ:SGHT – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.
Profitability
This table compares Owlet and Sight Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Owlet | -11.11% | -53.97% | -13.77% |
| Sight Sciences | -32.13% | -43.91% | -22.20% |
Analyst Recommendations
This is a summary of current ratings and price targets for Owlet and Sight Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Owlet | 1 | 1 | 4 | 0 | 2.50 |
| Sight Sciences | 1 | 2 | 5 | 0 | 2.50 |
Owlet presently has a consensus target price of $12.00, indicating a potential upside of 271.52%. Sight Sciences has a consensus target price of $10.31, indicating a potential downside of 2.46%. Given Owlet’s higher probable upside, equities research analysts plainly believe Owlet is more favorable than Sight Sciences.
Volatility and Risk
Owlet has a beta of 2.17, indicating that its share price is 117% more volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.44, indicating that its share price is 144% more volatile than the S&P 500.
Valuation & Earnings
This table compares Owlet and Sight Sciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Owlet | $112.85 million | 0.86 | -$39.68 million | ($0.68) | -4.75 |
| Sight Sciences | $88.39 million | 6.65 | -$38.43 million | ($0.52) | -20.33 |
Sight Sciences has lower revenue, but higher earnings than Owlet. Sight Sciences is trading at a lower price-to-earnings ratio than Owlet, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
72.6% of Owlet shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 36.2% of Owlet shares are owned by company insiders. Comparatively, 30.4% of Sight Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Owlet beats Sight Sciences on 7 of the 13 factors compared between the two stocks.
About Owlet
Owlet develops connected baby-monitoring products designed to give parents information about an infant’s sleep and well-being. Its offerings include the Dream Sock, a wearable monitor that tracks sleep-related readings, and Owlet Cam cameras, which provide video and audio monitoring through the company’s app. The company’s products combine wearable sensors, cameras and mobile software to help families monitor their babies at home. The Dream Sock has FDA clearance to monitor pulse rate and oxygen saturation in infants from 1 to 18 months of age.
About Sight Sciences
Sight Sciences is a medical technology company that develops and commercializes devices for ophthalmic care, with a focus on glaucoma and dry eye disease. Its products are designed to support minimally invasive procedures and address underlying causes of these conditions. The company’s portfolio includes the OMNI Surgical System, used in procedures to reduce eye pressure in patients with glaucoma, and TearCare, a device-based treatment for evaporative dry eye associated with meibomian gland dysfunction.
Receive News & Ratings for Owlet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Owlet and related companies with MarketBeat.com's FREE daily email newsletter.
